Artemether-lumefantrine exposure in HIV-infected nigerian subjects on nevirapine-containing antiretroviral therapy

Sunil Parikh*, Fatai Fehintola, Liusheng Huang, Alexander Olson, Waheed A. Adedeji, Kristin M. Darin, Gene D. Morse, Robert L. Murphy, Babafemi O. Taiwo, Olusegun O. Akinyinka, Isaac F. Adewole, Francesca T. Aweeka, Kimberly K. Scarsi

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Coadministration of nevirapine-based antiretroviral therapy (ART) and artemether-lumefantrine is reported to result in variable changes in lumefantrine exposure. We conducted an intensive pharmacokinetic study with 11 HIV-infected adults who were receiving artemether-lumefantrine plus nevirapine-based ART, and we compared the results with those for 16 HIV-negative adult historical controls. Exposure to artemether and lumefantrine was significantly lower and dihydroartemisinin exposure was unchanged in subjects receiving nevirapine-based ART, compared with controls. Nevirapine exposure was unchanged before and after artemether-lumefantrine administration.

Original languageEnglish (US)
Pages (from-to)7852-7856
Number of pages5
JournalAntimicrobial agents and chemotherapy
Issue number12
StatePublished - Dec 1 2015

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology


Dive into the research topics of 'Artemether-lumefantrine exposure in HIV-infected nigerian subjects on nevirapine-containing antiretroviral therapy'. Together they form a unique fingerprint.

Cite this